Investor Presentaiton

Expanding CTDMO Pipeline Drives Strong Growth Ahead "T" 167 Testing Customers (TTM) I I Autolo- I Allo- gous CAR-T I genic I CAR-T In-vivo CAR-T Allograft Cell TIL Viral Vector Others 1 Therapy 17 9 7 1 2 12 4 52 Preclinical & Phase I "D" 5 2 2 1 10 Phase II 2 3 1 1 7 Phase III "M" To come in Commercial 2023 2H ? Wuxi AppTec 药明康德

View entire presentation